Drug · GLP-1 / incretin · GLP-1 / incretin · Known compound
Orforglipron structure · mechanism
Oral non-peptide small-molecule GLP-1RA — modality bridge like Lipfendra in PCSK9.
Orforglipron 2D structure
- Role
- Drug
- Mechanism class
- GLP-1 / incretin
- Parent scaffold
- GLP-1 incretin pharmacophore
- Indication
- Oral non-peptide GLP-1RA · Investigational
- Structure source
- Catalog seed (external identifier on file)
- PubChem CID
- 166024334
- FDA / EMA
- Investigational
- ClinicalTrials.gov
- orforglipron
- Regulatory status
- P3 · Investigational · ClinicalTrials.gov · ClinicalTrials.gov
Hand-written analysis
Mechanism
오르포글리프론은 비펩타이드 경구 GLP-1 수용체 작용제입니다. 주사 펩타이드가 아니라 소분자입니다. 위배출·식욕·포도당 의존 인슐린은 같은 약리 축입니다.
Medicinal chemistry
헤테로사이클 소분자로 세마글루타이드의 지방산-펩타이드와 완전히 다릅니다. 경구 생체이용이 설계 목표입니다.
Indication · context
당뇨·체중 경구 인크레틴 후보입니다. /briefs/glp1-incretin과 함께 읽습니다.
SMILES
CC1=C(C(=O)N2CCCC2)C(=NN1c3ccc(C(=O)O)cc3)c4ccc(OC(F)(F)F)cc4Tags
Related compounds
Comparisons · briefs
External IDs · BioMoa
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.